Dose and regimen for hdm2-p53 interaction inhibitors

• 收藏
• 分享

专利权人:

Novartis AG

发明人:

Stephane Ferretti,Nelson Guerreiro,Sebastien Jeay,Astrid Jullion,Christophe Meille,Jens Wuerthner

申请号：

US16461005

公开号：

US20190298719A1

申请日:

2017.11.14

申请国别(地区):

US

年份:

2019

代理人:

摘要：

The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/